Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study

M. Hamadani, M. Coleman, R. Boccia, J. Duras, M. Hutchings, PL. Zinzani, R. Cordoba, MB. Oreiro, V. Williams, H. Liu, M. Stouffs, P. Langmuir, JM. Sancho

. 2023 ; 41 (5) : 848-857. [pub] 20230726

Language English Country England, Great Britain

Document type Multicenter Study, Clinical Trial, Phase I, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000532

Grant support
Incyte Corporation

Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL). CITADEL-102 (NCT03039114), a phase 1, multicenter study, assessed the efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with R/R FL. Patients were ≥18 years of age with histologically confirmed and documented CD20-positive FL, and R/R to previous rituximab-containing treatment regimens. Part one (safety run-in) determined the maximum tolerated dose of parsaclisib in combination with standard dosage regimens of obinutuzumab and bendamustine. Part two (dose expansion) was an open-label, single-group design evaluating safety, tolerability (primary endpoint), and efficacy (secondary endpoint) of parsaclisib combination therapy. Twenty-six patients were enrolled in CITADEL-102 and all patients received parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine. One patient in safety run-in experienced a dose-limiting toxicity of grade 4 QT interval prolongation that was considered related to parsaclisib. Eight patients (30.8%) discontinued treatment due to treatment-emergent adverse events (TEAEs) of colitis (2 [7.7%]), alanine aminotransferase and aspartate aminotransferase increase (both in one patient [3.8%]), neutropenia, thrombocytopenia, QT prolongation, tonsil cancer, and maculopapular rash (each 1 [3.8%]). The most common reported TEAEs were pyrexia (53.8%), neutropenia (50.0%), and diarrhea (46.2%). Twenty-three patients (88.5%) experienced grade 3 or 4 TEAEs; the most common were neutropenia (34.6%), febrile neutropenia (23.1%), and thrombocytopenia (19.2%). Seventeen patients (65.4%) had a complete response and 3 patients (11.5%) had a partial response, for an objective response rate of 76.9%. Overall, results from CITADEL-102 suggest that the combination of parsaclisib with obinutuzumab and bendamustine did not result in unexpected safety events, with little evidence of synergistic toxicity, and demonstrated preliminary efficacy in patients with R/R FL who progressed following prior rituximab-containing regimens.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000532
003      
CZ-PrNML
005      
20240313104459.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.3209 $2 doi
035    __
$a (PubMed)37496298
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hamadani, Mehdi $u Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA $1 https://orcid.org/000000015372510X
245    10
$a Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study / $c M. Hamadani, M. Coleman, R. Boccia, J. Duras, M. Hutchings, PL. Zinzani, R. Cordoba, MB. Oreiro, V. Williams, H. Liu, M. Stouffs, P. Langmuir, JM. Sancho
520    9_
$a Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL). CITADEL-102 (NCT03039114), a phase 1, multicenter study, assessed the efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with R/R FL. Patients were ≥18 years of age with histologically confirmed and documented CD20-positive FL, and R/R to previous rituximab-containing treatment regimens. Part one (safety run-in) determined the maximum tolerated dose of parsaclisib in combination with standard dosage regimens of obinutuzumab and bendamustine. Part two (dose expansion) was an open-label, single-group design evaluating safety, tolerability (primary endpoint), and efficacy (secondary endpoint) of parsaclisib combination therapy. Twenty-six patients were enrolled in CITADEL-102 and all patients received parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine. One patient in safety run-in experienced a dose-limiting toxicity of grade 4 QT interval prolongation that was considered related to parsaclisib. Eight patients (30.8%) discontinued treatment due to treatment-emergent adverse events (TEAEs) of colitis (2 [7.7%]), alanine aminotransferase and aspartate aminotransferase increase (both in one patient [3.8%]), neutropenia, thrombocytopenia, QT prolongation, tonsil cancer, and maculopapular rash (each 1 [3.8%]). The most common reported TEAEs were pyrexia (53.8%), neutropenia (50.0%), and diarrhea (46.2%). Twenty-three patients (88.5%) experienced grade 3 or 4 TEAEs; the most common were neutropenia (34.6%), febrile neutropenia (23.1%), and thrombocytopenia (19.2%). Seventeen patients (65.4%) had a complete response and 3 patients (11.5%) had a partial response, for an objective response rate of 76.9%. Overall, results from CITADEL-102 suggest that the combination of parsaclisib with obinutuzumab and bendamustine did not result in unexpected safety events, with little evidence of synergistic toxicity, and demonstrated preliminary efficacy in patients with R/R FL who progressed following prior rituximab-containing regimens.
650    _2
$a lidé $7 D006801
650    12
$a folikulární lymfom $x patologie $7 D008224
650    _2
$a bendamustin hydrochlorid $7 D000069461
650    _2
$a rituximab $7 D000069283
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a neutropenie $x chemicky indukované $7 D009503
650    12
$a trombocytopenie $x etiologie $7 D013921
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coleman, Morton $u Clinical Research Alliance Inc., Westbury, New York, USA
700    1_
$a Boccia, Ralph $u Center for Cancer and Blood Disorders, Bethesda, Maryland, USA
700    1_
$a Duras, Juraj $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Hutchings, Martin $u Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Zinzani, Pier Luigi, $d 1959- $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy $1 https://orcid.org/0000000221122651 $7 xx0314852
700    1_
$a Cordoba, Raul $u Lymphoma Unit, Department of Hematology, Fundación Jimenez Diaz University Hospital, Madrid, Spain
700    1_
$a Oreiro, Mariana Bastos $u Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
700    1_
$a Williams, Vanessa $u Incyte Corporation, Wilmington, Delaware, USA
700    1_
$a Liu, Huiqing $u Incyte Corporation, Wilmington, Delaware, USA
700    1_
$a Stouffs, Michael $u Incyte Corporation, Wilmington, Delaware, USA
700    1_
$a Langmuir, Peter $u Incyte Corporation, Wilmington, Delaware, USA
700    1_
$a Sancho, Juan-Manuel $u Clinical Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, IJC, Barcelona, Spain $1 https://orcid.org/0000000171686538
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 41, č. 5 (2023), s. 848-857
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37496298 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240313104454 $b ABA008
999    __
$a ok $b bmc $g 2049282 $s 1210226
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 5 $d 848-857 $e 20230726 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$p Incyte Corporation
LZP    __
$a Pubmed-20240109
Back

Find record

Citation metrics

Archiving options